NEW YORK (GenomeWeb News) – Bruker and Nextval are collaborating on the high-throughput screening of drugs and their metabolites using both companies' platforms, Bruker announced today.
Bruker's ultrafleXtreme MALDI-TOF/TOF mass spectrometer and Nextval's MassInsight technology will be used in the partnership.
The ultrafleXtreme "combines the acquisition speed of its 2 kHz smartbeam laser with its Perpetual Ion Source for optimum performance for low concentration high-throughput screening," Bruker said, adding that Nextval's screening technology will be integrated with Bruker's Compass software to maximize sample density and reduce sample analysis costs.
Meanwhile, Nextval's MassInsight technology, based on novel surface chemistries coupled with microarray acoustic deposition methods, addresses needs in the pharmaceutical and testing and industrial markets.
Based in San Diego, Nextval develops high-throughput, high-content, mass-based screening assays. The firm was recently was awarded a Phase II SBIR grant to further develop and commercialize the MassInsight technology for high-throughput enzyme assays.
Financial and other terms of the deal were not disclosed.